Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rockwell Medical (RMTI) Cash from Financing Activities (2016 - 2025)

Rockwell Medical's Cash from Financing Activities history spans 16 years, with the latest figure at -$1.1 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 137.93% year-over-year to -$1.1 million; the TTM value through Dec 2025 reached $4.3 million, down 42.13%, while the annual FY2025 figure was $4.3 million, 42.13% down from the prior year.
  • Cash from Financing Activities reached -$1.1 million in Q4 2025 per RMTI's latest filing, down from $6.7 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $26.8 million in Q2 2022 to a low of -$6.0 million in Q4 2022.
  • Average Cash from Financing Activities over 5 years is $1.9 million, with a median of -$549000.0 recorded in 2021.
  • Peak YoY movement for Cash from Financing Activities: crashed 162300.0% in 2021, then soared 447150.0% in 2022.
  • A 5-year view of Cash from Financing Activities shows it stood at -$1.6 million in 2021, then plummeted by 268.47% to -$6.0 million in 2022, then skyrocketed by 87.6% to -$742000.0 in 2023, then soared by 476.28% to $2.8 million in 2024, then plummeted by 137.93% to -$1.1 million in 2025.
  • Per Business Quant, the three most recent readings for RMTI's Cash from Financing Activities are -$1.1 million (Q4 2025), $6.7 million (Q3 2025), and -$650000.0 (Q2 2025).